Emcure Pharmaceuticals ↗

Emcure reported revenue of ~₹9,322 crore in FY26, reflecting a YoY increase of 18%, driven by strong performance across international markets and steady growth in the domestic business. International revenues grew by 22% YoY to ₹5,177 crore, led by growth across Europe (26%), Emerging Markets (22%) and Canada (19%). Growth was supported by market share gains, new product launches, healthy Antiretroviral (ARV) order execution, portfolio expansion and benefits from the integration of the

Emcure has a diversified product portfolio spanning both chronic and acute therapeutic areas, with a strong focus on high -value segments such as women's health, cardiology, diabetes, oncology, nephrology, CNS , and HIV therapies. The company continues to strengthen its presence across these segments through product development, strategic partnerships and in -licensing initiatives, while also maintaining a meaningful presence in anti -infectives, respiratory, nutri tion, and other acute therapie

Emcure continues to demonstrate strong geographical diversification, with sales spanning over 80 countries. This wide international footprint provides a balanced mix of domestic and export revenues, helping the company mitigate risks associated with economic fluctuations in single region. Emcure has maintained steady growth in key markets , such as India, Europe, and Canada, supported by its strategic investments and operational expansion.

Emcure continues to maintain a comfortable capital structure, supported by healthy profitability and strong cash accrual generation, despite a rise in debt levels in FY26. Total debt (including lease liabilities) increased to ₹1,519 crore as on March 31, 2026, from ₹1,022 crore as on March 31, 2025, primarily due to higher working capital borrowings and fresh foreign currency loans at the subsidiary level. Leverage was further impacted by the transfer of licences related to the Manx UK/Europe po

Within the group, Emcure, Gennova , and Zuventus have manufacturing facilities while other subsidiaries are engaged in warehousing and marketing of drugs manufactured by Emcure or other companies in various geographies. At a consolidated level, Emcure has 13 manufacturing facilities across India , which are capable of producing pharmaceutical and biopharmaceutical products of a wide range of dosage forms, including oral solids, oral liquids, injectables including lipid, liposomal, lyophilised

Emcure benefits from an experienced leadership team with a long-standing track record in the pharmaceutical industry. The company is led by Satish Mehta, a first-generation entrepreneur with over four decades of experience. Namita Thapar, who oversees the consumer wellness business, brings strong academic and professional credentials, including an MBA from Duke University and qualification as a Chartered Accountant. Samit Mehta, Chief Operating officer, holds degrees in commerce and

Emcure operates in a competitive environment across both domestic and international markets. The pharmaceutical industry faces pricing challenges, evolving regulations, and heightened attention to product quality and performance. Globally, the sector i s subject to regulatory oversight due to its impact on public health, requiring companies to comply with approval standards, manufacturing norms, and safety protocols.

Emcure is exposed to foreign exchange fluctuation risk due to its significant international operations and revenue streams denominated in major global currencies such as the US Dollar (USD), Euro (EUR), British Pound (GBP), and Canadian Dollar (CAD). Changes in currency rates can affect the company’s financial performance, including revenue and profitability. To manage this exposure, Emcure offsets foreign currency payables, such as trade obligations and loans, against foreign currency receivabl